Summit will take scenic route up FDA mountain after regulator recommends more trials for C. diff therapy

Summit will take scenic route up FDA mountain after regulator recommends more trials for C. diff therapy

Source: 
Fierce Biotech
snippet: 

Summit Therapeutics’ troubled C. difficile medicine may have a path forward after the FDA cleared a section of trail—however, it’s going to be a steep climb.

The California biotech met with the agency last week to discuss lead asset ridinilazole, which failed to outperform the common antibiotic vancomycin in a phase 3 clinical trial at the end of 2021. Summit has been looking for a way to advance the asset anyway, pitching potential partnerships or an acquisition as a way forward in March.